Please use this identifier to cite or link to this item:
http://sgc.anlis.gob.ar/handle/123456789/2525
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gulin, Julián Ernesto Nicolás | es |
dc.contributor.author | Bisio, Margarita María Catalina | es |
dc.contributor.author | Rocco, Daniela | es |
dc.contributor.author | Altcheh, Jaime | es |
dc.contributor.author | Solana, María Elisa | es |
dc.contributor.author | Garcia-Bournissen, Facundo | es |
dc.date.accessioned | 2023-03-08T16:50:47Z | - |
dc.date.available | 2023-03-08T16:50:47Z | - |
dc.date.issued | 2022 | - |
dc.identifier.uri | http://sgc.anlis.gob.ar/handle/123456789/2525 | - |
dc.description | Fil: Gulin, Julián Ernesto Nicolás. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-Gobierno de la Ciudad de Buenos Aires (GCBA), Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutiérrez, Ministerio de Salud; Buenos Aires, Argentina | es |
dc.description | Fil: Bisio, Margarita María Catalina. Instituto Nacional de Parasitología (INP) 'Dr. Mario Fatala Chaben'-Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) 'Dr. Carlos G. Malbrán', CONICET; Buenos Aires, Argentina | es |
dc.description | Fil: Rocco, Daniela. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-Gobierno de la Ciudad de Buenos Aires (GCBA), Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutiérrez, Ministerio de Salud; Buenos Aires, Argentina | es |
dc.description | Fil: Altcheh, Jaime. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)-Gobierno de la Ciudad de Buenos Aires (GCBA), Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños "Dr. Ricardo Gutiérrez, Ministerio de Salud; Buenos Aires, Argentina | es |
dc.description | Fil: Solana, María Elisa. Instituto de Microbiología y Parasitología Médica (IMPaM), Universidad de Buenos Aires; Buenos Aires, Argentina | es |
dc.description | Fil: García-Bournissen, Facundo. Division of Pediatric Clinical Pharmacology, Department of Pediatrics, Schulich School of Medicine & Dentistry, University of Western Ontario; Canadá | es |
dc.description.abstract | Drug repurposing and combination therapy have been proposed as cost-effective strategies to improve Chagas disease treatment. Miltefosine (MLT), a synthetic alkylphospholipid initially developed for breast cancer and repositioned for leishmaniasis, is a promising candidate against Trypanosoma cruzi infection. This study evaluates the efficacy of MLT as a monodrug and combined with benznidazole (BZ) in both in vitro and in vivo models of infection with T. cruzi (VD strain, DTU TcVI). MLT exhibited in vitro activity on amastigotes and trypomastigotes with values of IC50 = 0.51 µM (0.48 µM; 0,55 µM) and LC50 = 31.17 µM (29.56 µM; 32.87 µM), respectively. Drug interaction was studied with the fixed-ration method. The sum of the fractional inhibitory concentrations (ΣFICs) resulted in ∑FIC= 0.45 for trypomastigotes and ∑FIC= 0.71 for amastigotes, suggesting in vitro synergistic and additive effects, respectively. No cytotoxic effects on host cells were observed. MLT efficacy was also evaluated in a murine model of acute infection alone or combined with BZ. Treatment was well tolerated with few adverse effects, and all treated animals displayed significantly lower mean peak parasitemia and mortality than infected non-treated controls (p<0.05). The in vivo studies showed that MLT led to a dose-dependent parasitostatic effect as monotherapy which could be improved by combining with BZ, preventing parasitemia rebound after a stringent immunosuppression protocol. These results support MLT activity in clinically relevant stages from T. cruzi, and it is the first report of positive interaction with BZ, providing further support for evaluating combined schemes using MLT and exploring synthetic alkylphospholipids as drug candidates. | es |
dc.language.iso | en | es |
dc.relation.ispartof | Frontiers in cellular and infection microbiology | es |
dc.relation.ispartofseries | Front Cell Infect Microbiol;2022(12):1-12 | - |
dc.subject | Enfermedad de Chagas | es |
dc.subject | Trypanosoma Cruzi | es |
dc.subject | Antiparasitarios | es |
dc.subject | Quimioterapia Combinada | es |
dc.subject | Reposicionamiento de Medicamentos | es |
dc.subject | Antiprotozoarios | es |
dc.title | Miltefosine and Benznidazole Combination Improve Anti-Trypanosoma cruzi In Vitro and In Vivo Efficacy | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.3389/fcimb.2022.855119 | - |
item.cerifentitytype | Publications | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.openairetype | Artículo | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
Appears in Collections: | Artículos |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10.3389fcimb.2022.855119.pdf | 1.37 MB | Adobe PDF | View/Open |
Page view(s)
18
checked on May 11, 2024
Download(s)
1
checked on May 11, 2024
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.